Sulkowski MS, et al. - Researchers, in this phase 2, open-label ACCORDION study, investigated the efficacy, safety and pharmacokinetics of a 6- or 8-week regimen of simeprevir, daclatasvir and sofosbuvir in treatment-naïve patients with chronic hepatitis C virus (HCV) genotype (GT) 1 infection and either early-stage fibrosis or compensated cirrhosis. Findings revealed that the three direct-acting antiviral regimen of simeprevir, daclatasvir and sofosbuvir was safe and well tolerated in these patients.